Current drug research reviews · 2026
Functional Effects of Cromakalim on Aortic Tissue in STZ-Diabetic Rats: Impact of Insulin Treatment.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ozaydın Fuat Nihat
Аннотация
INTRODUCTION: K+ channels play a key role in the development of the vasodilation response, which is compromised in diabetes.
METHODS: In this study, the effects of the potassium channel activator cromakalim on aortic function were investigated in streptozotocin (STZ)-diabetic rats at short (1 week), medium (8 weeks), and long-term (14 weeks) durations, including a group treated with insulin for 14 weeks.
RESULTS: Compared with the control group, cromakalim-induced concentration-dependent vasodilation was reduced in the aortas of 8 and 14-week streptozotocin-diabetic rats (p < 0.05). Daily insulin treatment during the long-term (14 weeks) durations normalized the vasodilation response to cromakalim in the aortas of 14-week streptozotocin-diabetic rats.
DISCUSSION: Studies with cromakalim on diabetic rat aortic K+ channels are limited. Dose-dependent cromakalim-induced vasodilation was investigated in 8- and 12-week STZ-diabetic rat aortas and was found to be reduced. The impaired vasodilation responses were improved in the STZ-diabetic group with chronic insulin treatment. The results of these studies were similar to those of our study.
CONCLUSION: These findings indicate that potassium channel activity and vascular vasodilation ability decrease in the aortas of streptozotocin-diabetic rats depending on the duration of diabetes. In contrast, potassium channel activity and vascular vasodilation ability return to normal with insulin treatment in 14-week streptozotocin-diabetic aortas.
METHODS: In this study, the effects of the potassium channel activator cromakalim on aortic function were investigated in streptozotocin (STZ)-diabetic rats at short (1 week), medium (8 weeks), and long-term (14 weeks) durations, including a group treated with insulin for 14 weeks.
RESULTS: Compared with the control group, cromakalim-induced concentration-dependent vasodilation was reduced in the aortas of 8 and 14-week streptozotocin-diabetic rats (p < 0.05). Daily insulin treatment during the long-term (14 weeks) durations normalized the vasodilation response to cromakalim in the aortas of 14-week streptozotocin-diabetic rats.
DISCUSSION: Studies with cromakalim on diabetic rat aortic K+ channels are limited. Dose-dependent cromakalim-induced vasodilation was investigated in 8- and 12-week STZ-diabetic rat aortas and was found to be reduced. The impaired vasodilation responses were improved in the STZ-diabetic group with chronic insulin treatment. The results of these studies were similar to those of our study.
CONCLUSION: These findings indicate that potassium channel activity and vascular vasodilation ability decrease in the aortas of streptozotocin-diabetic rats depending on the duration of diabetes. In contrast, potassium channel activity and vascular vasodilation ability return to normal with insulin treatment in 14-week streptozotocin-diabetic aortas.